ID   DEFPL_PSENR             Reviewed;          95 AA.
AC   Q53I06;
DT   08-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   24-MAY-2005, sequence version 1.
DT   23-FEB-2022, entry version 57.
DE   RecName: Full=Fungal defensin plectasin {ECO:0000303|PubMed:16222292, ECO:0000303|PubMed:19414576, ECO:0000303|PubMed:19472324, ECO:0000303|PubMed:20508130};
DE   Flags: Precursor;
GN   Name=DEF;
OS   Pseudoplectania nigrella (Ebony cup) (Peziza nigrella).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Pezizomycetes;
OC   Pezizales; Sarcosomataceae; Pseudoplectania.
OX   NCBI_TaxID=96584;
RN   [1] {ECO:0000312|PDB:1ZFU}
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF N-TERMINUS, STRUCTURE BY
RP   NMR OF 56-95, FUNCTION, MASS SPECTROMETRY, AND DISULFIDE BONDS.
RX   PubMed=16222292; DOI=10.1038/nature04051;
RA   Mygind P.H., Fischer R.L., Schnorr K.M., Hansen M.T., Soenksen C.P.,
RA   Ludvigsen S., Raventos D.S., Buskov S., Christensen B., De Maria L.,
RA   Taboureau O., Yaver D., Elvig-Joergensen S.G., Soerensen M.V.,
RA   Christensen B.E., Kjaerulf S., Frimodt-Moller N., Lehrer R.I., Zasloff M.,
RA   Kristensen H.-H.;
RT   "Plectasin is a peptide antibiotic with therapeutic potential from a
RT   saprophytic fungus.";
RL   Nature 437:975-980(2005).
RN   [2]
RP   PHARMACEUTICAL.
RX   PubMed=19414576; DOI=10.1128/aac.01584-08;
RA   Andes D., Craig W., Nielsen L.A., Kristensen H.H.;
RT   "In vivo pharmacodynamic characterization of a novel plectasin antibiotic,
RT   NZ2114, in a murine infection model.";
RL   Antimicrob. Agents Chemother. 53:3003-3009(2009).
RN   [3]
RP   FUNCTION, 3D-STRUCTURE MODELING, MUTAGENESIS OF ASP-67; TYR-84; ALA-86;
RP   GLY-88 AND LYS-93, BINDING TO MEMBRANE INTERFACE, AND BINDING TO LIPID II.
RX   PubMed=20508130; DOI=10.1126/science.1185723;
RA   Schneider T., Kruse T., Wimmer R., Wiedemann I., Sass V., Pag U.,
RA   Jansen A., Nielsen A.K., Mygind P.H., Raventos D.S., Neve S., Ravn B.,
RA   Bonvin A.M., De Maria L., Andersen A.S., Gammelgaard L.K., Sahl H.G.,
RA   Kristensen H.H.;
RT   "Plectasin, a fungal defensin, targets the bacterial cell wall precursor
RT   Lipid II.";
RL   Science 328:1168-1172(2010).
RN   [4]
RP   FUNCTION.
RX   PubMed=25568977; DOI=10.3390/toxins7010034;
RA   Xiang F., Xie Z., Feng J., Yang W., Cao Z., Li W., Chen Z., Wu Y.;
RT   "Plectasin, first animal toxin-like fungal defensin blocking potassium
RT   channels through recognizing channel pore region.";
RL   Toxins 7:34-42(2015).
RN   [5] {ECO:0000312|PDB:3E7R, ECO:0000312|PDB:3E7U}
RP   X-RAY CRYSTALLOGRAPHY (1.0 ANGSTROMS) OF 56-95 OF L- AND D-PLECTASIN,
RP   FUNCTION, AND SYNTHESIS OF 56-95.
RX   PubMed=19472324; DOI=10.1002/pro.127;
RA   Mandal K., Pentelute B.L., Tereshko V., Thammavongsa V., Schneewind O.,
RA   Kossiakoff A.A., Kent S.B.;
RT   "Racemic crystallography of synthetic protein enantiomers used to determine
RT   the X-ray structure of plectasin by direct methods.";
RL   Protein Sci. 18:1146-1154(2009).
RN   [6] {ECO:0000312|PDB:6K50, ECO:0000312|PDB:6K51}
RP   STRUCTURE BY NMR OF 56-95 OF PLECTASIN DERIVATIVE NZ2114, AND MUTAGENESIS
RP   OF 64-ASP--GLN-69.
RA   Wang J.H., Mao R.Y., Liu X.H.;
RT   "Solution structure of plectasin derivative NZ2114.";
RL   Submitted (MAY-2019) to the PDB data bank.
CC   -!- FUNCTION: Antimicrobial peptide that potently acts against several
CC       species of Gram-positive bacteria (PubMed:16222292, PubMed:19472324).
CC       It selectively inhibits peptidoglycan biosynthesis through complex
CC       formation with the cell wall precursor lipid II (1:1 molar ratio) thus
CC       inhibiting cell wall synthesis (PubMed:20508130). It does not disrupt
CC       cell membranes (PubMed:20508130). Is especially active against numerous
CC       clinical isolates of S.pneumoniae, including all 90 different serotypes
CC       and isolates resistant to clinically used antibiotics
CC       (PubMed:16222292). In vitro, shows considerable selectivity for
CC       bacteria over mammalian cells (PubMed:16222292). The peptide
CC       synthesized in D-amino acids does not show antibacterial activity
CC       (PubMed:19472324). In vitro, acts on voltage-gated potassium channels
CC       by moderately inhibiting mammalian Kv1.3/KCNA3 (IC(50)=2.8 uM), and
CC       moderately inhibiting others potassium channels (PubMed:25568977).
CC       {ECO:0000269|PubMed:16222292, ECO:0000269|PubMed:25568977}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305}. Host cell membrane
CC       {ECO:0000269|PubMed:20508130}.
CC   -!- MASS SPECTROMETRY: Mass=4398.8; Method=Electrospray;
CC       Evidence={ECO:0000269|PubMed:16222292};
CC   -!- PHARMACEUTICAL: Plectasin could be used as a possible antibiotic,
CC       especially against S.pneumoniae infections.
CC       {ECO:0000305|PubMed:16222292}.
CC   -!- PHARMACEUTICAL: An improved derivative NZ2114 can be used as an
CC       antibiotic for the methicillin-resistant S.aureus (MRSA).
CC       {ECO:0000305|PubMed:19414576}.
CC   -!- MISCELLANEOUS: In mice infected by S.pneumoniae, it has an efficacy
CC       comparable to vancomycin in the peritoneal model and to penicillin in
CC       the pneumonia model. {ECO:0000269|PubMed:16222292}.
CC   -!- SIMILARITY: Belongs to the invertebrate defensin family. Type 2
CC       subfamily. {ECO:0000255|PROSITE-ProRule:PRU00710}.
CC   -!- WEB RESOURCE: Name=The antimicrobial peptide database;
CC       URL="https://wangapd3.com/database/query_output.php?ID=00549";
DR   EMBL; AJ964941; CAI83768.1; -; mRNA.
DR   PDB; 1ZFU; NMR; -; A=56-95.
DR   PDB; 3E7R; X-ray; 1.00 A; L=56-95.
DR   PDB; 3E7U; X-ray; 1.35 A; X=56-95.
DR   PDB; 6K50; NMR; -; A=56-95.
DR   PDB; 6K51; NMR; -; A=56-95.
DR   PDBsum; 1ZFU; -.
DR   PDBsum; 3E7R; -.
DR   PDBsum; 3E7U; -.
DR   PDBsum; 6K50; -.
DR   PDBsum; 6K51; -.
DR   SMR; Q53I06; -.
DR   TCDB; 1.C.47.2.1; the insect/fungal defensin (insect/fungal defensin) family.
DR   EvolutionaryTrace; Q53I06; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0015459; F:potassium channel regulator activity; IEA:UniProtKB-KW.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR   CDD; cd00107; Knot1; 1.
DR   Gene3D; 3.30.30.10; -; 1.
DR   InterPro; IPR001542; Defensin_invertebrate/fungal.
DR   InterPro; IPR003614; Scorpion_toxin-like.
DR   InterPro; IPR036574; Scorpion_toxin-like_sf.
DR   Pfam; PF01097; Defensin_2; 1.
DR   SUPFAM; SSF57095; SSF57095; 1.
DR   PROSITE; PS51378; INVERT_DEFENSINS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antibiotic; Antimicrobial;
KW   Cleavage on pair of basic residues; Defensin; Direct protein sequencing;
KW   Disulfide bond; Host cell membrane; Host membrane;
KW   Ion channel impairing toxin; Membrane; Pharmaceutical;
KW   Potassium channel impairing toxin; Secreted; Signal; Toxin;
KW   Voltage-gated potassium channel impairing toxin.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   PROPEP          24..55
FT                   /evidence="ECO:0000269|PubMed:16222292"
FT                   /id="PRO_0000042753"
FT   CHAIN           56..95
FT                   /note="Fungal defensin plectasin"
FT                   /id="PRO_0000042754"
FT   REGION          61..64
FT                   /note="Binds to membrane interface"
FT                   /evidence="ECO:0000305|PubMed:20508130"
FT   REGION          86..92
FT                   /note="Binds to membrane interface"
FT                   /evidence="ECO:0000305|PubMed:20508130"
FT   BINDING         59
FT                   /ligand="beta-D-GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-
FT                   L-Lys-D-Ala-D-Ala)-di-trans,octa-cis-undecaprenyl
FT                   diphosphate"
FT                   /ligand_id="ChEBI:CHEBI:60033"
FT                   /ligand_part="diphosphate group"
FT                   /ligand_part_id="ChEBI:CHEBI:68549"
FT                   /evidence="ECO:0000305|PubMed:20508130"
FT   BINDING         67
FT                   /ligand="beta-D-GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-
FT                   L-Lys-D-Ala-D-Ala)-di-trans,octa-cis-undecaprenyl
FT                   diphosphate"
FT                   /ligand_id="ChEBI:CHEBI:60033"
FT                   /evidence="ECO:0000305|PubMed:20508130"
FT   BINDING         73
FT                   /ligand="beta-D-GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-
FT                   L-Lys-D-Ala-D-Ala)-di-trans,octa-cis-undecaprenyl
FT                   diphosphate"
FT                   /ligand_id="ChEBI:CHEBI:60033"
FT                   /ligand_part="D-gamma-glutamate residue"
FT                   /evidence="ECO:0000305|PubMed:20508130"
FT   DISULFID        59..85
FT                   /evidence="ECO:0000269|PubMed:16222292,
FT                   ECO:0000269|PubMed:19472324, ECO:0007744|PDB:1ZFU,
FT                   ECO:0007744|PDB:3E7U"
FT   DISULFID        70..92
FT                   /evidence="ECO:0000269|PubMed:16222292,
FT                   ECO:0000269|PubMed:19472324, ECO:0007744|PDB:1ZFU,
FT                   ECO:0007744|PDB:3E7U"
FT   DISULFID        74..94
FT                   /evidence="ECO:0000269|PubMed:16222292,
FT                   ECO:0000269|PubMed:19472324, ECO:0007744|PDB:1ZFU,
FT                   ECO:0007744|PDB:3E7U"
FT   MUTAGEN         64..69
FT                   /note="DEDDMQ->NEDDLR: Plectasin derivative NZ2114;
FT                   increase in antibacterial spectrum by including the
FT                   methicillin-resistant A.aureus (MRSA)."
FT                   /evidence="ECO:0000269|PubMed:19414576, ECO:0000305|Ref.6"
FT   MUTAGEN         67
FT                   /note="D->A,C,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y: Complete
FT                   loss of antibacterial activity."
FT                   /evidence="ECO:0000269|PubMed:20508130"
FT   MUTAGEN         84
FT                   /note="Y->A,C,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W: Complete
FT                   loss of antibacterial activity."
FT                   /evidence="ECO:0000269|PubMed:20508130"
FT   MUTAGEN         86
FT                   /note="A->C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y: Complete
FT                   loss of antibacterial activity."
FT                   /evidence="ECO:0000269|PubMed:20508130"
FT   MUTAGEN         86
FT                   /note="A->G: No change of antibacterial activity."
FT                   /evidence="ECO:0000269|PubMed:20508130"
FT   MUTAGEN         88
FT                   /note="G->A,C,D,E,F,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y: Complete
FT                   loss of antibacterial activity."
FT                   /evidence="ECO:0000269|PubMed:20508130"
FT   MUTAGEN         93
FT                   /note="K->A,C,D,E,F,G,H,I,L,M,N,P,Q,S,T,V,W,Y: Complete
FT                   loss of antibacterial activity."
FT                   /evidence="ECO:0000269|PubMed:20508130"
FT   MUTAGEN         93
FT                   /note="K->R: No change of antibacterial activity."
FT                   /evidence="ECO:0000269|PubMed:20508130"
FT   TURN            57..59
FT                   /evidence="ECO:0007829|PDB:6K51"
FT   STRAND          62..64
FT                   /evidence="ECO:0007829|PDB:1ZFU"
FT   HELIX           67..76
FT                   /evidence="ECO:0007829|PDB:3E7R"
FT   STRAND          82..86
FT                   /evidence="ECO:0007829|PDB:3E7R"
FT   TURN            87..90
FT                   /evidence="ECO:0007829|PDB:3E7R"
FT   STRAND          91..95
FT                   /evidence="ECO:0007829|PDB:3E7R"
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000255; -; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00710; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:16222292; FLO; 19-DEC-2019.
**EV ECO:0000269; PubMed:19414576; FLO; 18-DEC-2019.
**EV ECO:0000269; PubMed:19472324; FLO; 19-DEC-2019.
**EV ECO:0000269; PubMed:20508130; FLO; 19-DEC-2019.
**EV ECO:0000269; PubMed:25568977; FLO; 17-DEC-2019.
**EV ECO:0000303; PubMed:16222292; FLO; 16-DEC-2019.
**EV ECO:0000303; PubMed:19414576; FLO; 19-DEC-2019.
**EV ECO:0000303; PubMed:19472324; FLO; 16-DEC-2019.
**EV ECO:0000303; PubMed:20508130; FLO; 19-DEC-2019.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**EV ECO:0000305; PubMed:16222292; FLO; 16-DEC-2019.
**EV ECO:0000305; PubMed:19414576; FLO; 19-DEC-2019.
**EV ECO:0000305; PubMed:20508130; FLO; 20-DEC-2019.
**EV ECO:0000305; Ref.6; FLO; 19-DEC-2019.
**EV ECO:0000312; PDB:1ZFU; FLO; 16-DEC-2019.
**EV ECO:0000312; PDB:3E7R; FLO; 16-DEC-2019.
**EV ECO:0000312; PDB:3E7U; FLO; 16-DEC-2019.
**EV ECO:0000312; PDB:6K50; FLO; 18-DEC-2019.
**EV ECO:0000312; PDB:6K51; FLO; 18-DEC-2019.
**EV ECO:0007744; PDB:1ZFU; FLO; 19-DEC-2019.
**EV ECO:0007744; PDB:3E7U; FLO; 19-DEC-2019.
**EV ECO:0007829; PDB:1ZFU; -; 19-DEC-2019.
**EV ECO:0007829; PDB:3E7R; -; 08-JAN-2020.
**EV ECO:0007829; PDB:6K51; -; 08-JAN-2020.
**YY The difference between calculated (4401.99) and measured (4398.8)
**YY mass cannot be explained by annotated PTMs.
**ZA SYP/KAX, 14-OCT-2005;
**ZB FLO, 25-MAR-2020; FLO, 26-MAY-2021;
SQ   SEQUENCE   95 AA;  10254 MW;  882903AB610AB018 CRC64;
     MQFTTILSIG ITVFGLLNTG AFAAPQPVPE AYAVSDPEAH PDDFAGMDAN QLQKRGFGCN
     GPWDEDDMQC HNHCKSIKGY KGGYCAKGGF VCKCY
//
